IMDX (Insight Molecular Diagnostics) Stock Based Compensation: $2.54 Mil (TTM As of Mar. 2026)


IMDX Insight Molecular Diagnostics Inc IMDX
49 GF Score
Price $5.92
GF Value $1.25
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Insight Molecular Diagnostics Stock Based Compensation?

Insight Molecular Diagnostics IMDX +8.46% 49 Stock Based Compensation is $2.54 Mil as of Mar. 2026. GuruFocus rates IMDX with a GF Score™ of 49/100 and a GF Value™ of $1.25 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Insight Molecular Diagnostics's Stock Based Compensation for the three months ended in Mar. 2026 was $0.65 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was $2.54 Mil.

Insight Molecular Diagnostics Stock Based Compensation Related Terms

Insight Molecular Diagnostics Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Insight Molecular Diagnostics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Insight Molecular Diagnostics Stock Based Compensation Chart

Insight Molecular Diagnostics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.84 10.04 2.89 1.91 2.38

Insight Molecular Diagnostics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.49 0.58 0.56 0.76 0.65
IMDX
49GF Score
Insight Molecular Diagnostics Inc IMDX
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Insight Molecular Diagnostics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.54 Mil.

What does a Stock Based Compensation of $2.54 Mil mean?
Insight Molecular Diagnostics (IMDX) has a Stock Based Compensation of $2.54 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Insight Molecular Diagnostics and its competitors.
Is Insight Molecular Diagnostics' Stock Based Compensation too high?
Insight Molecular Diagnostics' current Stock Based Compensation is $2.54 Mil. Overall, Insight Molecular Diagnostics has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Insight Molecular Diagnostics' Stock Based Compensation compare to XGN and BDSX?
Insight Molecular Diagnostics' Stock Based Compensation of $2.54 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Medical Diagnostics & Research company?
A good Stock Based Compensation depends on the Medical Diagnostics & Research industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Insight Molecular Diagnostics and its competitors. Insight Molecular Diagnostics's current Stock Based Compensation is $2.54 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insight Molecular Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Insight Molecular Diagnostics (IMDX) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.25, compared to a current price of $5.92 — trading 373.2% above its estimated fair value. The current Stock Based Compensation is $2.54 Mil. Insight Molecular Diagnostics' overall GF Score™ is 49/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Insight Molecular Diagnostics (IMDX), the current Stock Based Compensation is $2.54 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Insight Molecular Diagnostics (IMDX) Overvalued in 2026?

Based on GuruFocus' analysis, Insight Molecular Diagnostics stock appears to be overvalued. The current stock price of $5.92 is trading 373.2% above its estimated GF Value™ of $1.25. GuruFocus considers Insight Molecular Diagnostics to be Significantly Overvalued.

Key valuation signals for IMDX:

  • Stock Based Compensation: $2.54 Mil
  • GF Value™: $1.25 vs. price of $5.92 (373.2% above fair value)
  • GF Score™: 49/100 with 8 warning signs

No single metric tells the full story. See the IMDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Insight Molecular Diagnostics Business Description

Other Exchanges 0KCC:UK7OC0:Germany
Address 2 International Plaza Drive, Suite 510, Nashville, TN, USA, 37217
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
49GF Score

Get the complete analysis for IMDX

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.92
Price
$1.25
GF Value